The Randomized OPTIMAL-ACT Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT03772613
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 180 participants
- Sponsor
- Registry
-
NCT03772613
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03772613. Randomized; double masking; primary purpose treatment. Start 2019-02-08 (actual); primary completion 2021-10-25 (actual). Results posted on 2023-04-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Randomized OPTIMAL-ACT Trial
- Condition
- Coronary Artery Disease
- Condition
- Ischemic Heart Disease
- Condition
- Anticoagulant-induced Bleeding
- Condition
- Coronary Syndrome
- Intervention (Drug)
- Unfractionated heparin
- Lead sponsor
- Mayo Clinic
Record details
- Record id
cardio:ct-nct03772613- Content hash
7365b8b6c84472ce4521e2ec13caa18f13d04dac372139fda6da1ca0a4f5390c